| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Over the last 12 months, insiders at TransCode Therapeutics, Inc. have bought $0 and sold $0 worth of TransCode Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at TransCode Therapeutics, Inc. have bought $133,068 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 98,000 shares for transaction amount of $49,980 was made by Dudley Robert Michael (Chief Executive Officer) on 2023‑09‑28.
| 2023-09-28 | Dudley Robert Michael | Chief Executive Officer | 98,000 4.2888% | $0.51 | $49,980 | -96.46% | ||
| 2023-09-28 | Fitzgerald Thomas A | Chief Financial Officer | 49,350 2.1597% | $0.51 | $25,169 | -96.46% | ||
| 2023-06-21 | Dudley Robert Michael | Chief Executive Officer | 12,000 0.0815% | $2.65 | $31,818 | -93.94% | ||
| 2023-06-20 | Dudley Robert Michael | Chief Executive Officer | 6,607 0.0443% | $2.55 | $16,847 | -93.73% | ||
| 2023-06-09 | Dudley Robert Michael | Chief Executive Officer | 19,000 0.131% | $2.76 | $52,440 | -93.23% | ||
| 2022-09-14 | Dudley Robert Michael | Chief Executive Officer | 20,000 0.1541% | $1.15 | $23,000 | -73.09% | ||
| 2022-06-16 | Fitzgerald Thomas A | Chief Financial Officer | 12,000 0.0932% | $1.27 | $15,240 | -63.79% | ||
| 2022-05-27 | Dudley Robert Michael | Chief Executive Officer | 28,000 0.2175% | $1.84 | $51,643 | -73.35% |
| Increased Positions | 3 | +18.75% | 14,263 | +46.8% |
| Decreased Positions | 6 | -37.5% | 30,306 | -99.44% |
| New Positions | 3 | New | 14,263 | New |
| Sold Out Positions | 5 | Sold Out | 30,046 | Sold Out |
| Total Postitions | 13 | -18.75% | 14,434 | -52.64% |
| Drw Securities, Llc | $101.00 | 1.17% | 11,702 | +11,702 | New | 2025-09-30 |
| Citigroup Inc | $14.00 | 0.16% | 1,586 | +1,586 | New | 2025-09-30 |
| Federation Des Caisses Desjardins Du Quebec | $8.00 | 0.1% | 975 | +975 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.01% | 142 | -260 | -64.68% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 10 | 0 | 0% | 2025-09-30 |
| Royal Bank Of Canada | $0 | <0.01% | 8 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | <0.01% | 8 | 0 | 0% | 2025-09-30 |
| Osaic Holdings, Inc. | $0 | 0% | 3 | 0 | 0% | 2025-09-30 |
| Fmr Llc | $0 | 0% | 0 | -3 | Sold Out | 2025-09-30 |
| Goldman Sachs Group Inc | $0 | 0% | 0 | -28,042 | Sold Out | 2025-09-30 |